Skip to main content

Table 1 Demographics and baseline characteristics of randomized patients

From: Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial

Characteristics Infusion group
(n= 120)
Bolus group
(n= 120)
P- value
Age (years) 44.9 ± 17.8 47.2 ± 16.3 0.503
Male 78 (65.0%) 83 (69.2%) 0.583
Weight (kg) 78 (70.0 to 90.0) 80 (72.0 to 95.5) 0.079
APACHE II 21.4 ± 7.9 22.1 ± 8.79 0.545
SOFA 10.4 ± 2.9 10.6 ± 3.5 0.738
GFR calculated by MDRD (ml/s) 1.20 (0.77 to 1.80) 1.19 (0.88 to 1.59) 0.813
Diagnostic group n (%)    
Cardiac surgery 4 (3.3%) 2 (1.7%) 0.685
Neurology and neurosurgery 3 (2.5%) 3 (2.5%) 1,000
Surgery 18 (15.0%) 30 (25.0%) 0.075
Gastroenterology 22 (18.3%) 14 (11.7%) 0.205
Traumatology 43 (35.8%) 45 (37.5%) 0.788
Respiratory failure 2 (1.7%) 7 (5.8%) 0.171
Circulatory failure 24 (20.0%) 18 (15.0%) 0.396
Other 4 (3.3%) 1 (0.8%) 0.370
Type of infection n (%)    
Not identified 0 (0.0%) 2 (1.6%) 0.498
Abdominal 23 (19.2%) 31 (25.8%) 0.357
Respiratory 66 (55.0%) 61 (50.8%) 0.605
Soft tissues, skin 5 (4.2%) 6 (5.0%) 1.000
Bloodstream 10 (8.3%) 11 (9.2%) 1.000
Uroinfection 11 (9.2%) 6 (5.0%) 0.314
Central nervous system 3 (2.5%) 2 (1.6%) 1.000
More sources 2 (1.6%) 1 (0.8%) 1.000
Nosocomial infection 110 (91.7%) 113 (94.2%) 0,616
Concomitant ATB therapy n (%) 58 (48.3%) 61 (50.8%) 0.796
Concomitant ATB therapy potentially active against GNB 11 (9.2%) 6 (5.0%) 0.314
Previous ATB therapy n (%) 114 (95.0%) 113 (94.2%) 1.000
Previous ATB therapy (days) 7.0 (6.0 to 8.0) 7.0 (6.0 to 8.0) 0.338
Number of previous ATB 3 (3 to 5) 4 (3 to 5) 0.509
Empiric therapy n (%) 6 (5.0%) 7 (5.8%) 1.000
Length of ICU stay before meropenem therapy (days) 9.0 (5.0 to 16.0) 7.0 (3.0 to 11.0) 0.036
Leucocytes (x 109/L) 15.9 (11.5 to 21.1) 14.1 (11.2 to 19.6) 0.437
CRP (mg/L) 155 (115 to 197) 199 (117 to 262) 0.090
  1. Values are presented as absolute (percentage) or mean ± standard deviation or median (interquartile range). APACHE II, Acute Physiology and Chronic Health Evaluation II; ATB, antibiotic; CRP, C-reactive protein; GFR, Glomerular filtration rate; GNB, Gram-negative bacteria; ICU, intensive care unit; MDRD, Modification of Diet in Renal Disease; SOFA, Sequential Organ Failure Assessment.